ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02688712|
Recruitment Status : Recruiting
First Posted : February 23, 2016
Last Update Posted : September 15, 2020
The purpose of this study is to see how effective and safe LY2157299, in combination with chemotherapy and radiation therapy, might be in treating rectal cancer. Also as part of this study, research will be done on tumor samples to see if it is possible to predict if patients will respond to treatment, and blood samples to look at the immune system response to study treatment.
About 50 people will take part in this study. The study treatment will be given over an 8 week period and the investigators will continue to collect your health information for up to 5 years, as part of this study
|Condition or disease||Intervention/treatment||Phase|
|Rectal Adenocarcinoma||Drug: LY2157299 Drug: Capecitabine Drug: Fluorouracil Procedure: Tumor specific mesorectal excision||Phase 2|
This is a prospective Phase II study to test the efficacy of LY2157299 in combination with neoadjuvant chemoradiation in patients with rectal adenocarcinoma. This study will test the hypothesis that LY2157299 will improve effector T cell tumor infiltration and activity resulting in improved pathologic response rates. The investigators propose that this improved immune response will result in improved disease-free and overall survival.
The objectives are:
- Determine the rate of pathologic complete response in patients with locally advanced rectal adenocarcinoma treated with neoadjuvant chemoradiation and the investigational agent LY2157299
- Correlate immunoscore changes prior to therapy, during therapy, and at surgical resection with pathologic response and MRI parameters
- Immune monitoring to evaluate potential biomarkers of treatment success.
Eligible patients will have histologically confirmed rectal adenocarcinoma, AJCC Stage IIA IIIC or AJCC Stage IV appropriate for consideration of primary rectal tumor resection. Patients will undergo a forceps biopsy of the rectal mass as part of the diagnostic workup as well as undergo staging evaluation including an MRI with additional study sequences. Enrolled patients will receive a 14 day course of LY2157299 followed by a repeat biopsy and MRI with study sequences. In this trial the investigators plan to use the maximum tolerated dose of LY2157299 established in human clinical trials, 300mg delivered as 150mg P.O. BID. On day 15 patients will begin chemoradiation with either 5-FU (fluorouracil ) or capecitabine (Xeloda®). On day 29, patients will undergo another fourteen day course of LY2157299 concurrent with their ongoing chemoradiation.
Patients will undergo 50.4 to 54Gy of radiation in 1.8Gy daily fractions delivered Monday through Friday for a total of 28-30 fractions. The acceptable duration of chemoradiation, including treatment breaks or delays, is up to 8 weeks total. Six to ten weeks after completing their neoadjuvant therapy, patient will undergo a tumor specific mesorectal excision as per standard of care with evaluation of pathologic response rate. Patients will be followed for disease-free survival, progression free survival, local recurrence, and overall survival. A three patient safety lead-in will be performed, where a six week safety period following completion of radiation will be completed prior to enrolling subsequent patients.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma|
|Study Start Date :||June 2016|
|Estimated Primary Completion Date :||December 2021|
|Estimated Study Completion Date :||June 2022|
Experimental: LY2157299 + Chemoradiation + Surgery
Patients will receive a 14 day course of LY2157299. On day 15 patients will begin chemoradiation treatment with Capecitabine or Fluorouracil. On day 29, patients will undergo another fourteen day course of LY2157299 concurrent with their ongoing chemoradiation treatment. Six to ten weeks after completing their neoadjuvant therapy, patient will undergo a tumor specific mesorectal excision as per standard of care.
Small molecule inhibitor of transforming growth factor-beta signaling pathway
Other Name: Galunisertib
Other Name: Xeloda
Other Name: 5-fluorouracil , 5-FU, Adrucil, Efudex, Fluoroplex
Procedure: Tumor specific mesorectal excision
Tumor specific mesorectal excision
- Evaluation of pathologic response [ Time Frame: Patients should be evaluated for response at surgery and every 3 months for 2 years and then every 6 months at year three and four. All patients will be followed for survival until death or 5 years post-treatment (whichever comes first) ]Complete response is defined as no viable tumor cells identified.
- Immunoscore (utilizing tumor tissue) [ Time Frame: Screening Visit, Day 15 Visit and Day of Surgery ]For the immunoscore, a value of 0 or 1 is assigned to each cell population of interest with 0 corresponding to a poor immune infiltrate and 1 corresponding to a favorable immune infiltrate as determined by immunohistochemistry.
- MRI Parameters [ Time Frame: Screening Visit and Day 15 Visit ]Investigators will test a minimum of three MRI parameters including but not limited to ADC and f_p from the IVIM sequence, and Ktrans from the DCE sequence.
- Immunologic monitoring parameters [ Time Frame: Days 1, 15, 22, 29, 43, 57 Visits, and Day of Surgery. ]The immunologic monitoring parameters will be combined to arrive at an aggregated measure of "pro-tumor immune environment" or "anti-tumor immune environment" using cell counts derived from flow cytometry of peripheral blood and serum measures of inflammation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02688712
|Contact: Larissa Lundgren||(503) 215-2614||Larisa.Lundgren@providence.org|
|United States, Oregon|
|Providence Cancer Center||Recruiting|
|Portland, Oregon, United States, 97213|
|Contact: Larissa Lundgren 503-215-2614 Larisa.Lundgren@providence.org|
|Sub-Investigator: Walter J. Urba, M.D., Ph.D|
|Sub-Investigator: Rachel Sanborn, MD|
|Sub-Investigator: Todd Crocenzi, MD|
|Sub-Investigator: Bernard Fox, Ph.D|
|Sub-Investigator: Michael Gough, Ph.D.|
|Sub-Investigator: Stephen Bader, MD|
|Sub-Investigator: Alice Wang-Chesebro, MD|
|Sub-Investigator: Matthew Solhjem, MD|
|Sub-Investigator: Rui Li, MD, PhD|
|Sub-Investigator: Rom Leidner, MD|
|Sub-Investigator: Marka Crittenden, MD, PhD|
|Sub-Investigator: Steven Seung, MD, PhD|
|Sub-Investigator: Mark Whiteford, MD|
|Sub-Investigator: David Page, MD|
|Sub-Investigator: John Godwin, MD|
|Principal Investigator:||Kristina Young, MD, PhD||Providence Health & Services|
|Principal Investigator:||Todd Crocenzi, MD||Providence Health & Services|